ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,071.63
      0.02%
      US Tech 100
      16,896.40
      -0.96%
      Dow Jones
      38,460.92
      -0.11%
      Brent Oil
      87.555
      0.38%
      Bitcoin
      63,948.35
      -0.52%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Vaxcyte Inc (PCVX)

      7. Vaxcyte Inc (PCVX) News

      PCVX Vaxcyte Inc

      60.30
      0.00 (0.00%)
      Pre Market
      Last Updated: 04:09:34
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      Vaxcyte Inc PCVX NASDAQ Common Stock
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      0.00 0.00% 60.30 04:09:34
      Open Price Low Price High Price Close Price Prev Close
      60.30
      more quote information »

      Recent News

      Date Time Source Heading
      4/02/202416:05GLOBEVaxcyte to Present at the 23rd Annual Needham Virtual..
      3/04/202421:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      3/04/202421:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      3/04/202421:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      3/04/202408:30GLOBEVaxcyte Completes Enrollment of Phase 2 Study Evaluating..
      3/01/202416:02EDGAR2Form 144 - Report of proposed sale of securities
      3/01/202416:00EDGAR2Form 144 - Report of proposed sale of securities
      2/27/202416:58EDGAR2Form S-8 - Securities to be offered to employees in employee..
      2/27/202416:02EDGAR2Form 8-K - Current report
      2/27/202416:01GLOBEVaxcyte Reports Fourth Quarter and Full Year 2023 Financial..
      2/20/202416:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/15/202416:05GLOBEVaxcyte to Report Fourth Quarter and Full Year 2023..
      2/05/202417:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/05/202417:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/02/202418:39GLOBEVaxcyte Announces Closing of $862.5 Million Public Offering..
      2/01/202416:07EDGAR2Form 144 - Report of proposed sale of securities
      2/01/202416:06EDGAR2Form 144 - Report of proposed sale of securities
      2/01/202416:05GLOBEVaxcyte to Present at the Guggenheim Healthcare Talks | 6th..
      1/31/202417:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
      1/31/202417:19EDGAR2Form 8-K - Current report
      1/30/202423:37GLOBEVaxcyte Announces Pricing of $750 Million Public Offering
      1/30/202416:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
      1/30/202416:01GLOBEVaxcyte Announces Commencement of Proposed Public Offering..
      1/29/202408:30GLOBEVaxcyte Completes Enrollment of Phase 1/2 Study Evaluating..
      1/16/202416:01GLOBEVaxcyte Appoints Whitney Jones as Chief People Officer
      1/04/202416:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/04/202416:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/04/202416:01GLOBEVaxcyte Provides Clinical and Regulatory Progress Update on..
      1/02/202416:04EDGAR2Form 144 - Report of proposed sale of securities
      1/02/202416:03EDGAR2Form 144 - Report of proposed sale of securities
      12/11/202316:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      12/07/202316:15EDGAR2Form 144 - Report of proposed sale of securities
      12/05/202316:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      12/04/202318:35GLOBEVAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in..
      12/01/202316:12EDGAR2Form 144 - Report of proposed sale of securities
      11/29/202316:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      11/29/202316:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
      11/28/202308:32EDGAR2Form 8-K - Current report
      11/28/202308:30GLOBEVaxcyte Appoints Jacks Lee to Board of Directors
      11/27/202316:05EDGAR2Form 8-K - Current report
      11/27/202316:00GLOBEVaxcyte Exercises Option and Enters into Manufacturing..
      11/09/202308:30GLOBEVaxcyte Doses First Participants in Phase 1/2 Clinical Study..
      11/06/202316:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      11/06/202316:07EDGAR2Form 8-K - Current report
      11/06/202316:03GLOBEVaxcyte Reports Third Quarter 2023 Financial Results and..
      11/03/202316:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      11/01/202316:07EDGAR2Form 144 - Report of proposed sale of securities
      10/31/202316:05GLOBEVaxcyte to Present at Upcoming Investor Conferences
      10/19/202309:29DJNVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine..
      10/19/202308:30GLOBEVaxcyte Announces FDA Clearance of Investigational New Drug..

      Your Recent History

      NASDAQ
      PCVX
      Vaxcyte
      Delayed Upgrade Clock